Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Last trade$6.58
Day change+$0.15 (+2.33%)
Day range$6.42 – $6.99
Volume234,610
Market cap$139M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$138.7M
Price / earnings
—
Price / book
0.68×
Price / sales
2.76×
EV / sales
1.87×
EV / EBITDA
-2.05×
Profitability
Earnings per share
-$1.91
Return on assets
-15.58%
Return on equity
-20.06%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
10.46×
Quick ratio
10.46×
Cash ratio
1.81×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$62.15M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RNA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$15.32M
$3M
$19.64M
$860K
$12.48M
$3.85M
$1.57M
$2.97M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$15.32M
$3M
$19.64M
$860K
$12.48M
$3.85M
$1.57M
$2.97M
Selling, general and administrative
$8.15M
$10.28M
$20.26M
$88.74M
$46.33M
$36.86M
$33.6M
$28.34M
Research and development
$13.8M
$15.34M
$16.66M
$166.6M
$154.95M
$138.13M
$99.49M
$95.63M
Total operating expenses
$21.95M
$25.62M
$36.92M
$255.34M
$201.28M
$174.99M
$133.09M
$123.96M
Operating income
-$6.63M
-$22.62M
-$17.28M
-$254.48M
-$188.81M
-$171.14M
-$131.52M
-$120.99M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$4.27M
-$20.19M
-$16.63M
-$237.1M
-$174.44M
-$157.32M
-$115.77M
-$102.26M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$4.27M
-$20.19M
-$16.63M
-$237.1M
-$174.44M
-$157.32M
-$115.77M
-$102.26M
Net income attributable to common shareholders
-$4.27M
-$20.19M
-$16.63M
-$237.1M
-$174.44M
-$157.32M
-$115.77M
-$102.26M
EBITDA
-$6.28M
-$22.28M
-$17.13M
-$252.98M
-$187.75M
-$170.33M
-$130.73M
-$120.25M
Basic earnings per share
-$0.25
-$1.18
-$0.97
-$1.54
-$1.27
-$1.21
-$0.90
-$0.79
Diluted earnings per share
-$0.25
-$1.18
-$0.97
-$1.54
-$1.27
-$1.21
-$0.90
-$0.79
Recent news
Company coverage with links to the original publishers.
Investor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed mergers and acquisitions. The firm is seeking increased consideration for shareholders and additional disclosures regarding the transactions.
Monteverde & Associates PC, a class action securities firm, is investigating four proposed mergers: The Brand House Collective's sale to Bed Bath & Beyond, Avidity Biosciences' acquisition by Novartis for $72 per share, NorthWestern Energy Group's sale to Black Hills Corp, and Two Harbors Investment Corp's merger with UWM Holdings Corporation. The firm is seeking shareholders with concerns about these transactions ahead of upcoming shareholder votes.
Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies involving mergers and acquisitions.
Novartis anticipates 5-6% annual sales growth from 2025-2030, raised peak sales projections for key drugs like Kisqali and Scemblix, and expects to maintain operating margins above 40% while planning significant U.S. infrastructure expansion.
Novartis reported Q3 2025 results with net sales rising 8% to $13.91 billion, driven by strong performance in key growth drugs like Kisqali and Kesimpta. The company reaffirmed its full-year guidance despite generic competition and announced a $12 billion acquisition of Avidity Biosciences.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.